Boston Scientific Corp. announced its Synergy bioabsorbable polymer stent has met its primary endpoint in a much anticipated pivotal trial in the U.S. and has shown to be non-inferior to its Promus Element Plus drug- eluting stent when treating coronary artery disease.
The company released data on its Evolve II study at the American Heart Association (AHA) Scientific Session 2014 in Chicago,...